Cosentyx copay assistance9/12/2023 The incidence of some types of infections appeared to be dose-dependent in clinical studies. A similar increase in risk of infection was seen in placebo-controlled trials in subjects with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. In placebo-controlled clinical trials in subjects with moderate to severe plaque psoriasis, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. Cases of anaphylaxis have been reported during treatment with COSENTYX.ĬOSENTYX may increase the risk of infections. Secukinumab or to any of the excipients in COSENTYX. Plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.ĬOSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.ĬOSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).ĬOSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA)ĬOSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.ĬOSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to COSENTYX ® (secukinumab) is indicated for the treatment of moderate to severe
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |